Ampio incorporates Luoxis Diagnostics, COO Josh Disbrow to be CEO if Luoxis Ampio Pharmaceuticals announced the incorporation and initiation of operations of Luoxis Diagnostics, a subsidiary of Ampio that will initially be funded through a private placement, with Ampio maintaining approximately 80% ownership post financing. Josh Disbrow, Ampio's COO, will assume the role of CEO of Luoxis. Details about the private placement will follow in the near future.
Ampio confirms sales agreement with Cantor Fitzgerald Ampio Pharmaceuticals entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald. CEO Michael Macaluso stated "During our most recent conference call, we stated that we are not currently raising money and that we have enough money to get us through 2016 and into 2017 and still complete all of our current objectives and nothing has changed since that conference call. The "at-the-market" program may be used opportunistically and as a contingency facility to strengthen our position post-Ampion trial data."